Pelthos Therapeutics Inc. (PTHS) Key Metrics
PTHS valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $77.1M
- Enterprise value
- $139.0M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 1.8
- Price / book
- 2.9
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 3.11
PTHS key metrics, 2020–2025
Fiscal year ended December 31, 2025 · U.S. dollarsPTHS returns How much profit the business earns on the capital it uses.
PTHS financial health Debt, liquidity and how easily interest is covered.
PTHS valuation history
PTHS returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
PTHS debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
PTHS cash returned to shareholders
PTHS price vs earnings per share
PTHS key metrics
2020–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Valuation | ||||||
| Market capitalization | $58.3M | — | — | — | — | — |
| Enterprise value | $75.1M | — | — | — | — | — |
| Price / sales | 3.5 | — | — | — | — | — |
| Price / book | 1.5 | — | — | — | — | — |
| EV / sales | 4.5 | — | — | — | — | — |
| Earnings yield | −74.3% | — | — | — | — | — |
| Free cash flow yield | −38.9% | — | — | — | — | — |
| Shareholder yield (dividends + buybacks) | 0.0% | — | — | — | — | — |
| Share price at fiscal year-end | $31.00 | $6.41 | — | — | — | — |
| Per share | ||||||
| Revenue per share | $8.93 | — | — | — | — | — |
| Earnings per share | −$23.04 | — | — | — | — | — |
| Operating cash flow per share | −$12.01 | — | — | — | — | — |
| Free cash flow per share | −$12.07 | — | — | — | — | — |
| Cash per share | $9.58 | — | — | — | — | — |
| Book value per share | $20.68 | — | — | — | — | — |
| Tangible book value per share | −$13.44 | — | — | — | — | — |
| Capex per share | $0.05 | — | — | — | — | — |
| Debt per share | $18.52 | — | — | — | — | — |
| Shares outstanding | 1.9M | — | — | — | — | — |
| Returns & profitability | ||||||
| Return on equity (ROE) | −239.6% | — | — | — | — | — |
| Return on invested capital (ROIC) | −93.8% | — | — | — | — | — |
| Return on assets (ROA) | −65.8% | — | — | — | — | — |
| Return on tangible assets | −65.4% | −581.0% | — | — | — | — |
| Free cash flow margin | −135.1% | — | — | — | — | — |
| Financial health | ||||||
| Total debt | $34.8M | $2.2M | $1.3M | $540,430 | — | — |
| Cash & short-term investments | $18.0M | $513,443 | $96,391 | $55,074 | — | — |
| Net debt | $16.8M | $1.7M | $1.2M | $485,356 | — | — |
| Debt / equity | 0.90 | — | — | — | — | — |
| Debt / assets | 0.27 | 1.60 | 13.16 | 9.81 | — | — |
| Current ratio | 2.03 | 0.34 | 0.01 | 0.01 | 0.00 | — |
| Quick ratio | 1.12 | 0.34 | 0.01 | 0.01 | 0.00 | — |
| Interest coverage | -10.8 | -9.6 | -13.2 | -16.5 | — | -807.8 |
| Working capital | $26.7M | −$2.7M | −$6.4M | −$3.7M | −$2.6M | — |
| Invested capital | $55.7M | −$1.0M | −$5.3M | −$3.2M | −$3.7M | — |
| Tangible asset value | −$25.3M | −$2.7M | −$6.4M | −$3.7M | −$3.7M | — |
| Net current asset value | −$38.8M | −$2.7M | −$6.4M | −$3.7M | −$3.7M | — |
| Graham net-net per share | −$29.28 | — | — | — | — | — |
| Capital allocation | ||||||
| Share buybacks (net) | $0 | $166,512 | $0 | — | — | — |
| Capex / revenue | 0.6% | — | — | — | — | — |
| Capex / depreciation | 0.04 | — | — | — | — | — |
| Stock-based compensation / revenue | 32.5% | — | — | — | — | — |
| R&D / revenue | 7.3% | — | — | — | — | 69.3% |
| SG&A / revenue | 220.8% | — | — | — | — | — |
| Efficiency | ||||||
| Days sales outstanding | 96.7 | — | — | — | — | — |
| Days of inventory on hand | 459.4 | — | — | — | — | — |
| Days payables outstanding | 95.2 | — | — | — | — | — |
| Cash conversion cycle (days) | 460.9 | — | — | — | — | — |
| Receivables turnover | 3.77 | 0.00 | — | — | — | — |
| Payables turnover | 3.84 | 0.00 | — | — | — | — |
| Inventory turnover | 0.79 | — | — | — | — | — |
| Asset turnover | 0.25 | 0.00 | 0.00 | 0.00 | — | — |
| Average receivables | $4.4M | $40,400 | — | — | — | — |
| Average payables | $2.4M | $3.3M | $3.8M | $2.8M | $2.6M | — |
| Average inventory | $11.8M | $0 | — | — | — | — |
| Intangibles / total assets | 49.2% | 0.0% | 0.0% | 0.0% | — | — |
Computed from PTHS's annual financial statements (latest annual report filed March 19, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
PTHS valuation and financial ratios
Pelthos Therapeutics earned a return on equity of −239.6% and a return on invested capital of −93.8% in fiscal 2025. It ended the year with $34.8 million of debt and $18.0 million in cash and short-term investments, net debt of $16.8 million.
See the PTHS income statement, the PTHS chart for price history, or the PTHS stock overview for the latest quote and news.
PTHS key metrics FAQ
What is Pelthos Therapeutics's return on equity?
Pelthos Therapeutics's return on equity (ROE) was −239.6% in fiscal 2025: net income of -$43.3 million on average shareholders' equity of $18.1 million.
What is Pelthos Therapeutics's ROIC?
Pelthos Therapeutics's return on invested capital was −93.8% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Pelthos Therapeutics have?
Pelthos Therapeutics had total debt of $34.8 million at the end of fiscal 2025, a debt-to-equity ratio of 0.90.
What is Pelthos Therapeutics's free cash flow yield?
Pelthos Therapeutics generated -$22.7 million of free cash flow in fiscal 2025, a free cash flow yield of −38.9% on its market value at year-end ($58.3 million).
What is Pelthos Therapeutics's current ratio?
Pelthos Therapeutics's current ratio was 2.03 at the end of fiscal 2025: current assets were 2.03 times current liabilities.